International Journal of Molecular Sciences | |
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia | |
Marialuisa Polillo1  Sara Galimberti2  Claudia Baratè2  Mario Petrini2  Romano Danesi1  Antonello Di Paolo1  | |
[1]Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Pisa, Via Roma 55, 56126 Pisa, Italy | |
[2] E-Mails: | |
[3]Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Via Roma 57, 56126 Pisa, Italy | |
[4] E-Mails: | |
关键词: pharmacogenetics; pharmacogenomics; chronic myeloid leukemia; imatinib; nilotinib; dasatinib; bosutinib; ponatinib; transmembrane transporter; | |
DOI : 10.3390/ijms160922811 | |
来源: mdpi | |
【 摘 要 】
Chronic myeloid leukemia was the first haematological neoplasia that benefited from a targeted therapy with imatinib nearly 15 years ago. Since then, several studies have investigated the role of genes, their variants (
【 授权许可】
CC BY
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190005921ZK.pdf | 693KB | download |